Table 2.
AEs reported by two or more subjects
| AE category | Number (%) of subjects | |||||
|---|---|---|---|---|---|---|
| Placebo (N = 8) |
5 mg AZD4831 (N = 8) |
10 mg AZD4831 (N = 8) |
15 mg AZD4831 (N = 8) |
45 mg AZD4831 (N = 5) |
Total AZD4831 (N = 29) |
|
| Subjects with any AE | 4 (50.0) | 2 (25.0) | 3 (37.5) | 3 (37.5) | 2 (40.0) | 10 (34.5) |
| Contact dermatitis | 0 | 0 | 2 (25.0) | 1 (12.5) | 0 | 3 (10.3) |
| Generalized maculopapular rash | 1 (12.5) | 0 | 0 | 2 (25.0) | 2 (40.0) | 4 (13.79) |
| Headache | 2 (25.0) | 1 (12.5) | 1 (12.5) | 0 | 1 (20.0) | 3 (10.3) |
| Dry throat | 0 | 0 | 0 | 1 (12.5) | 1 (20.0) | 2 (6.9) |
AE, adverse event.